60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP NASDAQ) stock market data APIs
$1.29
-0.02(-1.5%)
as of January 2, 2025
60 Degrees Pharmaceuticals, Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.
Prev. Close
1.31
Open
1.29
Volume
15 051
High
1.35
Low
1.29
52 wk Range
0.7015-13.56
Market Cap
2 964 K
Shares Outstanding
2 297 K
Revenue
441 K
EPS
-0.8676
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get 60 Degrees Pharmaceuticals, Inc. Common Stock data using free add-ons & libraries
Get 60 Degrees Pharmaceuticals, Inc. Common Stock Fundamental Data
60 Degrees Pharmaceuticals, Inc. Common Stock Fundamental data includes:
- Net Revenue: 441 K
- EBITDA: -8 893 385
- Earnings Per Share: -9
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get 60 Degrees Pharmaceuticals, Inc. Common Stock Earnings data
$
19.99
/mo.
What’s included:
- Latest Release: 2024-11-14
- EPS/Forecast: -0.87
Get 60 Degrees Pharmaceuticals, Inc. Common Stock End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
60 Degrees Pharmaceuticals, Inc. Common Stock News
New
60 Degrees Pharma Announces Type C Meeting with FDA to Discuss Development of Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease
Type C meeting will be to discuss a proposed Phase II study of tafenoquine for treatment of babesiosis Transmitted by ticks, babesiosis is a life-threatening parasitic disease increasing in frequency ...
60 Degrees Pharma to Present Review of Safety, Efficacy Data of 8-Aminoquinolines for Malaria and Babesiosis Treatment at ILADS Annual Scientific Meeting in Boston
60 Degrees Pharmaceuticals will present scientific poster on new, long-term safety data on the use of tafenoquine for malaria prevention at the ILADS 2023 annual scientific meeting60 Degrees Pharmaceu...
60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19, Pivots to Refocus on Commercialization of Treatments for Malaria and Tick-Borne Diseases
FDA advice to Company suggested execution of ACLR8-LR, a placebo-controlled Phase IIB study of tafenoquine in COVID-19 patients, may not be feasible in the U.S. Company will therefore focus efforts o...
60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA Requirements
Prompted by advice from FDA regarding study design, 60P Australia Pty Ltd, a majority-owned subsidiary of 60 Degrees Pharmaceuticals, has withdrawn its IND for ACLR8-LR, a Phase IIB study of the use o...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- 100 000+ API requests per day
- EOD Data - All World Extended
- Splits and Dividends
- Fundamental Data
- Bonds Data
- Options Data
- 1000+ currency pairs
- 1000+ cryptocurrency pairs
